Clinical Trial Search

Primary: Percentage of Lesions With Improvement as Assessed With the Global Aesthetic Improvement Scale (GAIS) — 76.2; 75.5 percentage of lesions

Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Objective Response Rate — 0 percentage of participants

Primary: Number of Participants With Technical Success — 5 Participants

Primary: Participants' Average Time Spent Looking at Stimuli According to Condition — 10.72; 10.07; 10.99; 9.53 seconds — p=<.05

Primary: Weight of Mothers — 88.65; 97.43; 85.96; 96.52 Kilograms

Primary: Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT) — -0.2112; -0.0859; -0.2185; -0.0800 pmol/mL — p=<0.001

Primary: Mean Susceptibility to Vaping Score — 2.16; 2.21; 2.36 score on a scale

Primary: Mullen Scales of Early Learning (MSEL) Composite Score — 73.63; 74.33; 77.04; 76.75 t-score — p=.77

Primary: Number of Participants Experiencing Acute Respiratory Decompensation — 0; 0 Participants

Primary: Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL — 0.49; 1.88 events/patient-year…

Primary: IOP of Study Eye Related to Safety — 16.547; 16.328; 16.241 mmHg

Primary: Pain Intensity as Assessed by the Numeric Rating Scale (NRS) — 7.4; 7.0; 7.3 score on a scale

Primary: IOP Related to Safety — 15.906; 16.452; 16.469 mmHg

Primary: Number of Days to Return to Full Unrestricted Athletic Participation — 11.0; 11.9 Days